Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE study: BRAF/MEK inhibitors in anaplastic thyroid cancer
jRCT1031240365Recruiting
- Sponsor
- Yokohama City University Hospital
- Start
- May 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial of 6MHP vaccine + dabrafenib + trametinib in anaplastic thyroid cancer (ATC), sponsored by Yokohama City University Hospital. Primary endpoint: 12-month survival rate in patients treated with BRAF inhibitors. Started May 2024; status: recruiting.
02
Drugs
6MHP vaccine + dabrafenib + trametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on jRCT1031240365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240365.